HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
PSME4
proteasome activator subunit 4
Chromosome 2 · 2p16.2
NCBI Gene: 23198Ensembl: ENSG00000068878.16HGNC: HGNC:20635UniProt: Q14997
92PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
DNA Repair
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
nucleoplasmnucleusprotein bindingDNA damage responseAlzheimer diseaseParalytic ileusintestinal obstructionbreast carcinoma
✦AI Summary

PSME4 (proteasome activator subunit 4) is a proteasome regulator that recognizes acetylated histones through its bromodomain-like region and promotes ATP- and ubiquitin-independent histone degradation. It functions by binding the proteasomal core via its C-terminus, opening the gated channel for substrate entry through an active gating mechanism. PSME4 plays dual roles: during spermatogenesis, it participates in histone exchange within the spermatoproteasome complex [UniProt annotation], and in somatic cells, it promotes histone degradation following DNA double-strand breaks as part of the DNA damage response. In cancer biology, PSME4 upregulation in non-small-cell lung carcinoma attenuates antigenic diversity and associates with immunotherapy resistance 1. In multiple myeloma, PSME4 is overexpressed in relapsed/refractory disease and represents a therapeutic target 2. PSME4 dysregulation has been identified as a biomarker in diverse pathological contexts: it shows differential methylation in first-episode schizophrenia 3, altered expression in heart failure where it may involve cell cycle and lysosomal pathways 4, and association with interstitial cystitis through gut-microbiota interactions 5. These findings suggest PSME4 regulates both constitutive and stress-responsive proteasomal degradation pathways with implications across reproductive biology, cancer, and systemic diseases.

Sources cited
1
PSME4 upregulation in NSCLC alters proteasome activity, attenuates antigenic diversity, and associates with lack of immunotherapy response
PMID: 37217651
2
PSME4/PA200 is a proteasome activator with dysregulation in multiple human diseases and potential as a therapeutic target
PMID: 36009043
3
PSME4 is overexpressed in relapsed/refractory multiple myeloma and its knockdown sensitizes MM cells to proteasome inhibitors
PMID: 35344764
4
PSME4 methylation differs between first-episode schizophrenia patients and controls, with lower methylation in patient group
PMID: 38886359
5
PSME4 is among the top three downregulated genes in ginsenoside-treated lens epithelial cells
PMID: 32046688
6
PSME4 is identified as a hub gene differentially expressed between interstitial cystitis patients and healthy individuals
PMID: 39399486
7
PSME4 is identified as a SUMOylation-related biomarker in heart failure with significant differential expression and involvement in cell cycle and lysosomal pathways
PMID: 41189222
8
PSME4 expression is modulated in the proteasome bounce-back response in cholangiocarcinoma cells treated with proteasome inhibitors
PMID: 38538281
Disease Associationsⓘ20
Alzheimer diseaseOpen Targets
0.33Weak
Paralytic ileusOpen Targets
0.28Weak
breast carcinomaOpen Targets
0.28Weak
intestinal obstructionOpen Targets
0.28Weak
aortic diseaseOpen Targets
0.25Weak
liver diseaseOpen Targets
0.24Weak
osteoarthritis, kneeOpen Targets
0.24Weak
smoking initiationOpen Targets
0.24Weak
Subdural hemorrhageOpen Targets
0.23Weak
Left bundle branch blockOpen Targets
0.23Weak
iron metabolism diseaseOpen Targets
0.22Weak
sleep apneaOpen Targets
0.19Weak
azoospermiaOpen Targets
0.10Weak
total knee arthroplastyOpen Targets
0.09Suggestive
HeterotaxiaOpen Targets
0.08Suggestive
spermatogenic failure 72Open Targets
0.08Suggestive
spermatogenic failure 65Open Targets
0.08Suggestive
spermatogenic failure, X-linked, 5Open Targets
0.08Suggestive
spermatogenic failure 27Open Targets
0.08Suggestive
spermatogenic failure 46Open Targets
0.08Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
POMPProtein interaction100%PSMC1Protein interaction100%PSMD14Protein interaction100%PSMD1Protein interaction100%PSMD2Protein interaction100%PSMD7Protein interaction100%
Tissue Expression6 tissues
Bone Marrow
100%
Heart
89%
Lung
68%
Liver
59%
Brain
41%
Ovary
40%
Gene Interaction Network
Click a node to explore
PSME4POMPPSMC1PSMD14PSMD1PSMD2PSMD7
PROTEIN STRUCTURE
Preparing viewer…
PDB6KWY · 2.72 Å · EM
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.39Moderately Constrained
pLIⓘ
1.00Intolerant
Observed/Expected LoF0.32 [0.26–0.39]
RankingsWhere PSME4 stands among ~20K protein-coding genes
  • #5,212of 20,598
    Most Researched92
  • #1,931of 17,882
    Most Constrained (LOEUF)0.39 · top quartile
Genes detectedPSME4
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC.
PMID: 37217651
Nat Cancer · 2023
1.00
2
The Proteasome Activator PA200/PSME4: An Emerging New Player in Health and Disease.
PMID: 36009043
Biomolecules · 2022
0.90
3
Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma.
PMID: 35344764
EBioMedicine · 2022
0.80
4
A novel blood-based epigenetic biosignature in first-episode schizophrenia patients through automated machine learning.
PMID: 38886359
Transl Psychiatry · 2024
0.70
5
Ginsenosides induce extensive changes in gene expression and inhibit oxidative stress-induced apoptosis in human lens epithelial cells.
PMID: 32046688
BMC Complement Med Ther · 2020
0.60